|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NIT1 |
Gene summary for NIT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NIT1 | Gene ID | 4817 |
| Gene name | nitrilase 1 | |
| Gene Alias | NIT1 | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006807 | UniProtAcc | Q86X76 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4817 | NIT1 | LZE4T | Human | Esophagus | ESCC | 8.11e-12 | 2.76e-01 | 0.0811 |
| 4817 | NIT1 | LZE7T | Human | Esophagus | ESCC | 1.58e-04 | 3.49e-01 | 0.0667 |
| 4817 | NIT1 | LZE8T | Human | Esophagus | ESCC | 3.36e-09 | 2.25e-01 | 0.067 |
| 4817 | NIT1 | LZE20T | Human | Esophagus | ESCC | 4.33e-04 | 1.47e-01 | 0.0662 |
| 4817 | NIT1 | LZE22T | Human | Esophagus | ESCC | 4.00e-02 | 2.58e-01 | 0.068 |
| 4817 | NIT1 | LZE24T | Human | Esophagus | ESCC | 6.77e-16 | 4.56e-01 | 0.0596 |
| 4817 | NIT1 | LZE21T | Human | Esophagus | ESCC | 5.74e-08 | 3.79e-01 | 0.0655 |
| 4817 | NIT1 | LZE6T | Human | Esophagus | ESCC | 1.19e-04 | 2.90e-01 | 0.0845 |
| 4817 | NIT1 | P1T-E | Human | Esophagus | ESCC | 4.83e-09 | 5.20e-01 | 0.0875 |
| 4817 | NIT1 | P2T-E | Human | Esophagus | ESCC | 4.20e-35 | 5.71e-01 | 0.1177 |
| 4817 | NIT1 | P4T-E | Human | Esophagus | ESCC | 1.90e-35 | 8.28e-01 | 0.1323 |
| 4817 | NIT1 | P5T-E | Human | Esophagus | ESCC | 2.00e-24 | 3.80e-01 | 0.1327 |
| 4817 | NIT1 | P8T-E | Human | Esophagus | ESCC | 1.33e-17 | 2.47e-01 | 0.0889 |
| 4817 | NIT1 | P9T-E | Human | Esophagus | ESCC | 1.97e-20 | 5.47e-01 | 0.1131 |
| 4817 | NIT1 | P10T-E | Human | Esophagus | ESCC | 5.90e-17 | 2.01e-01 | 0.116 |
| 4817 | NIT1 | P11T-E | Human | Esophagus | ESCC | 1.18e-08 | 4.03e-01 | 0.1426 |
| 4817 | NIT1 | P12T-E | Human | Esophagus | ESCC | 6.30e-18 | 3.68e-01 | 0.1122 |
| 4817 | NIT1 | P15T-E | Human | Esophagus | ESCC | 2.23e-24 | 5.28e-01 | 0.1149 |
| 4817 | NIT1 | P16T-E | Human | Esophagus | ESCC | 2.49e-21 | 3.54e-01 | 0.1153 |
| 4817 | NIT1 | P17T-E | Human | Esophagus | ESCC | 1.04e-09 | 4.19e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
| GO:004427021 | Liver | HCC | cellular nitrogen compound catabolic process | 303/7958 | 451/18723 | 9.76e-27 | 3.64e-24 | 303 |
| GO:004427016 | Oral cavity | OSCC | cellular nitrogen compound catabolic process | 256/7305 | 451/18723 | 9.67e-15 | 5.88e-13 | 256 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NIT1 | SNV | Missense_Mutation | rs760352516 | c.151N>A | p.Val51Met | p.V51M | Q86X76 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| NIT1 | SNV | Missense_Mutation | c.859N>C | p.Glu287Gln | p.E287Q | Q86X76 | protein_coding | tolerated(0.06) | benign(0.041) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| NIT1 | SNV | Missense_Mutation | c.859N>C | p.Glu287Gln | p.E287Q | Q86X76 | protein_coding | tolerated(0.06) | benign(0.041) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| NIT1 | SNV | Missense_Mutation | c.797N>T | p.Arg266Ile | p.R266I | Q86X76 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| NIT1 | SNV | Missense_Mutation | rs531981250 | c.541A>G | p.Thr181Ala | p.T181A | Q86X76 | protein_coding | deleterious(0.05) | possibly_damaging(0.665) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| NIT1 | SNV | Missense_Mutation | rs759711881 | c.415N>G | p.Thr139Ala | p.T139A | Q86X76 | protein_coding | tolerated(0.63) | benign(0.012) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NIT1 | SNV | Missense_Mutation | novel | c.488N>T | p.His163Leu | p.H163L | Q86X76 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| NIT1 | SNV | Missense_Mutation | c.387C>G | p.Phe129Leu | p.F129L | Q86X76 | protein_coding | tolerated(0.25) | benign(0.306) | TCGA-AG-A02X-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NIT1 | SNV | Missense_Mutation | rs375048732 | c.917N>A | p.Arg306Gln | p.R306Q | Q86X76 | protein_coding | tolerated(1) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NIT1 | SNV | Missense_Mutation | c.466G>A | p.Val156Met | p.V156M | Q86X76 | protein_coding | deleterious(0.04) | probably_damaging(0.977) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |